Blog

Home » Blog

Genomic Tests to Help Determine if the Cancer is Life-Threatening

Videos, Active Surveillance / By / / 1 minute of reading

Attached is a really interesting though somewhat long at 30 minutes video  (Published on Oct 22, 2013), on the emerging role of genomics in the management of newly diagnosed low risk PC. Dr. Denes discusses the PIVOT study, PSA testing yes or no, and then goes into a discussion on genomics testing as a factor in a decision whether to continue on active surveillance or seek further treatment It is a really clear and lucid presentation which I think anyone who has been recently diagnosed or those who are on active surveillance would benefit from listening to. View Video

Genomic Tests to Help Determine if the Cancer is Life-Threatening Read More »

Newsletter May 2015

Newsletters / By / / 1 minute of reading

Awareness: The PCCN-Toronto and Side by Side Prostate Cancer Support Groups Newsletter. In this Issue: New “Ask the Doctor” column – first column: Why PSA screening is still important – despite what you might read or hear. Do It For Dads – the 2015 Father’s Day Walk/Run Our Next Scotiabank Awareness Night – Dr. John Kell –  “Radical prostatectomy: Do differences in technique make a difference?” Blue Wrist Bands New guidelines in place regarding our Side by Side support group. Tell us what you think – take our website based survey 2015 Scotiabank Awareness Nights Schedule Read it by clicking

Newsletter May 2015 Read More »

Increased Risk of Diabetes among Patients Receiving Primary Androgen Deprivation Therapy for Clinically Localized Prostate Cancer.

Advanced Prostate Cancer, Hormone Therapy / By / / 1 minute of reading

Androgen deprivation therapy (ADT) may increase diabetes risk. As benefits of primary ADT (PADT) for localized PCa are controversial, and most PCa survivors are of advanced age with comorbidities, it is important to determine if PADT increases diabetes risk and what are the susceptibility factors. Read the article.  (Free UroToday login required.)

Increased Risk of Diabetes among Patients Receiving Primary Androgen Deprivation Therapy for Clinically Localized Prostate Cancer. Read More »

Five-year follow-up of active surveillance for prostate cancer: A Canadian community-based urological experience

Active Surveillance / By / / 1 minute of reading

The percentage of prostate cancer with low-risk characteristics has increased since the mid-1990s largely due to widespread prostate-specific antigen (PSA) screening. Over a similar period, the percentage of prostate cancer mortalities has reduced by more than 40%. There is now growing evidence that men with low-risk prostate cancer may not benefit from radical treatment. This has created controversy regarding PSA screening practices and the treatment of low-risk prostate cancer due to concerns of overdiagnosis and overtreatment. Active surveillance (AS) is an accepted alternative to immediate intervention for favourable-risk prostate cancer and it has shown promise in reducing overtreatment. Several large

Five-year follow-up of active surveillance for prostate cancer: A Canadian community-based urological experience Read More »

Scroll to Top